Paris-based Orakl Oncology has raised an oversubscribed $34 million (€31 million) Series A, co-led by Swedish investor ...
Paris-based Orakl Oncology has raised an oversubscribed $34 million (€31 million) Series A, co-led by Swedish investor ...
Austria continues to strengthen its position as one of Europe’s most dynamic life sciences locations. New infrastructure, a coordinated national cluster landscape and targeted funding initiatives ...
Germany-based biotech company SRTD Biotech has closed a €31.5 million seed funding round. At the heart of its approach is an ...
Swiss venture capital investor Redalpine has closed its eighth fund at $250 million. Redalpine Capital VIII reached its hard ...
London-based Kesmalea Therapeutics has raised $60 million (about €53.5 million) in a Series A-2 financing and rebranded as Oyster Therapeutics. The funding will support the development of an oral, ...
British biotech Neobe Therapeutics has raised $6.8 million (€6.1 million) in seed funding to develop engineered bacteria that ...
U.K. biotech Immunocore has reported an estimated 70% two-year survival rate among 17 evaluable first-line metastatic uveal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results